Conference of the International Clinical Hyperthermia Society 2012View this Special Issue
Conference Paper | Open Access
Meggyesházi Nóra, Andócs Gábor, Krenács Tibor, "Programmed Cell Death Induced by Modulated Electrohyperthermia", Conference Papers in Science, vol. 2013, Article ID 187835, 3 pages, 2013. https://doi.org/10.1155/2013/187835
Programmed Cell Death Induced by Modulated Electrohyperthermia
Background. Modulated electrohyperthermia (mEHT) is a noninvasive technique for targeted tumor treatment. Method. HT29 human colorectal carcinoma cell line xenografted to both femoral regions of BalbC/nu/nu mice was treated with a single shot OTM treatment. Histomorphologic, immunohistochemical analysis TUNEL assay, and R&D Apoptosis array were performed on tissue samples. Results. mEHT caused a selective tumor demolition. An upregulation of TRAIL-R2 and FAS was observed. Cleaved caspase-3 positive cells appear at the tumor periphery. Cytochrome c and AIF release was observed in line with massive TUNEL positivity. Conclusion. In HT29 colorectal cancer xenograft, mEHT caused massive caspase independent cell death.
Modulated electrohyperthermia (mEHT) is a noninvasive technique for targeted tumor treatment [1–4]. The capacitive coupled modulated radiofrequency enriches in the tumor tissue, because of its dielectric differences [5, 6], without harming the surrounding nonmalignant tissues. The possible mechanism of action of conventional hyperthermia on tumor models was previously slightly investigated and has not been fully evaluated . Already it was shown that mEHT has nontemperature dependent effect beside the temperature dependent one . Here, our aim was to detect the possible role of mEHT in tumor cell death.
HT29 human colorectal carcinoma cell line xenografted to both femoral regions of BalbC/nu/nu mice was treated with a single shot OTM treatment (LabEHY, Oncotherm Ltd, Páty, Hungary) for 30 minutes of approximately 1.5 cm diameter tumors. Sampling was made after 0, 1, 4, 8, 14, 24, 48, 72, 120, 168, and 216 h in 3 mice, each group by keeping 5 untreated animals. The temperature measurement was carried out during the treatment using optical probes (Luxtron FOT Lab Kit, LumaSense Technologies, Inc., CA, USA). The treated tumor core the treated tumor surface subcutaneously, the untreated tumor core and the rectal temperature was measured. The treated tumore core temperature was 41-42°C during the treatment. Histomorphologic (H&E), immunohistochemical analysis by cleaved caspase-3 (Cell Signaling, Danvers, MA), TRAIL-R2 (Cell Signaling), cytochrome c (Cell Signaling), and AIF (Cell Signaling) were completed on formalin fixed paraffin embedded tissue microarrays (TMA, TMA Master, 3DHISTECH Ltd., Budapest, Hungary) prepared from all samples. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay (Invitrogen, Carlsbad, CA) was performed on TMA at 24 h and 48 h after treatment of whole sections. R&D Apoptosis array (R&D, Minneapolis, MN) was carried out on the 8 h, 14 h, and 24 h treated and 24 h untreated samples. Results were analyzed using digital microscopy and were evaluated by ImageJ.
Modulated EHT caused a selective tumor demolition proceeding from the tumor centre. An upregulation of TRAIL-R2 and FAS was observed 8 h after treatment (Figure 1).
Cleaved caspase-3 positive cells (mostly leucocytes) only appeared at the tumor periphery at 4–14 h. Cytochrome c release was observed at 8–14 h after treatment. AIF nuclear translocalisation occurred at 14–24 h (Figure 2). Massive TUNEL positivity develops at 24–48 h after treatment. Heavy myeloperoxide and CD3 positive leukocyte infiltration ring was observed between 72–216 h, which possibly correlates to the tumor elimination.
In HT29 colorectal cancer xenograft, mEHT caused massive cell death, causing a caspase independent, AIF dependent programmed cell death subroutine.
Conflict of Interests
The authors declare no conflict of interests in this project.
- T. Feyerabend, G. J. Wiedemann, B. Jäger, H. Vesely, B. Mahlmann, and E. Richter, “Local hyperthermia, radiation, and chemotherapy in recurrent breast cancer is feasible and effective except for inflammatory disease,” International Journal of Radiation Oncology Biology Physics, vol. 49, no. 5, pp. 1317–1325, 2001.
- G. Fiorentini, P. Giovanis, S. Rossi et al., “A phase II clinical study on relapsed malignant gliomas treated with electro-hyperthermia,” In Vivo A, vol. 20, no. 6, pp. 721–724, 2006.
- G. Fiorentini and A. Szasz, “Hyperthermia today: electric energy, a new opportunity in cancer treatment,” Journal of Cancer Research and Therapeutics, vol. 2, no. 2, pp. 41–46, 2006.
- E. D. Hager, H. Dziambor, D. Höhmann, D. Gallenbeck, M. Stephan, and C. Popa, “Deep hyperthermia with radiofrequencies in patients with liver metastases from colorectal cancer,” Anticancer Research C, vol. 19, no. 4, pp. 3403–3408, 1999.
- B. Blad and B. Baldetorp, “Impedance spectra of tumour tissue in comparison with normal tissue; a possible clinical application for electrical impedance tomography,” Physiological Measurement, vol. 17, supplement 4, pp. A105–A115, 1996.
- B. Blad, P. Wendel, M. Jönsson, and K. Lindström, “An electrical impedance index to distinguish between normal and cancerous tissues,” Journal of Medical Engineering and Technology, vol. 23, no. 2, pp. 57–62, 1999.
- B. Hildebrandt, P. Wust, and O. Ahlers, “The cellular and molecular basis of hyperthermia,” Critical Reviews in Oncology/Hematology, vol. 43, no. 1, pp. 33–56, 2002.
- G. Andocs, H. Renner, L. Balogh, L. Fonyad, C. Jakab, and A. Szasz, “Strong synergy of heat and modulated electromagnetic field in tumor cell killing,” Strahlentherapie und Onkologie, vol. 185, no. 2, pp. 120–126, 2009.
Copyright © 2013 Meggyesházi Nóra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.